Deutsche Bank AG Acquires New Position in Denali Therapeutics Inc. $DNLI

Deutsche Bank AG acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 149,804 shares of the company’s stock, valued at approximately $3,853,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DNLI. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Denali Therapeutics during the second quarter worth about $26,000. Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics during the 2nd quarter valued at approximately $26,000. Global Retirement Partners LLC acquired a new stake in shares of Denali Therapeutics during the 2nd quarter valued at approximately $28,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the 3rd quarter worth approximately $29,000. Finally, State of Wyoming purchased a new stake in shares of Denali Therapeutics during the 2nd quarter worth approximately $29,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on DNLI. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Denali Therapeutics in a research report on Monday, May 11th. Wedbush reiterated an “outperform” rating and set a $26.00 target price on shares of Denali Therapeutics in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, Stifel Nicolaus set a $41.00 target price on Denali Therapeutics in a report on Monday, June 22nd. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.85.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares in the company, valued at $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.70% of the stock is owned by company insiders.

Denali Therapeutics Price Performance

DNLI opened at $24.93 on Wednesday. Denali Therapeutics Inc. has a 52-week low of $12.58 and a 52-week high of $27.30. The company has a 50 day moving average of $24.55 and a two-hundred day moving average of $21.64. The company has a market cap of $3.99 billion, a P/E ratio of -8.78 and a beta of 1.01. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the previous year, the company posted ($0.72) earnings per share. On average, analysts expect that Denali Therapeutics Inc. will post -2.59 earnings per share for the current year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.